Avacta Group plc: Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Positive safety profile of AVA6000 continues in the fourth cohort Analysis of six tumour biopsies confirms the tumour targeting potential of pre|CISION technology Avacta Group plc (AIM: AVCT)

Related Keywords

Alastair Smith ,Lily Jeffery ,Avacta Group ,Zyme Communications ,Safety Data Monitoring Committee ,Chief Executive Officer ,Avacta ,Group ,Nnounces ,Uccessful ,Completion ,Fourth ,Nose ,Escalation ,Va6000 ,Hase ,Linical ,Study ,